Bagshaw M A
Prog Clin Biol Res. 1984;153:493-512.
External beam irradiation has been used extensively in the treatment of primary prostatic carcinoma during the past 25 years. Actuarial survival rates of 79%, 58%, and 37% have been achieved at 5, 10, and 15 years, respectively, for patients with disease apparently limited to the prostate (nominal stage A and B; or T0, T1, and T2, status of lymph nodes unknown). The survival rates at the above intervals are 60%, 36%, and 22%, respectively, for patients with extracapsular extension (stage C, or T3 status of lymph nodes unknown). In more highly selected subgroups of patients, e.g., those with nodular lesions 1 cm or less in diameter, the survival stabilized at 80% by the 8th year, with the longest survivors now passing the 15th year. In 113 patients with nodular lesions occupying up to one half of one lobe, the probability of survival is just under 60% at 15 years. In a group of 51 staged Stanford patients, a study of the time to first evidence of metastases was comparable to the surgical group reported by the Uro-Oncology Research Group rather than the radiation therapy group, casting doubt that the difference in outcome between surgery and radiation therapy in stages A2 and B carcinoma of the prostate demonstrated in short-term follow-up by the Uro-Oncology Research Group is necessarily a fundamental observation. Both the clinical stage and the histopathologic grade can be correlated with lymphadenopathy, and lymphadenopathy, in turn, has a profound adverse influence on survival. Other factors which adversely affect survival include a delay in treatment of greater than six months, a radiation dose of less than 6500 rad and/or evidence of ureteral obstruction. The ability to sterilize the primary tumor with external beam irradiation appears related to the bulkiness of the disease, suggesting that, for larger tumors, the achievable dose by external beam therapy alone may be inadequate, and that some form of augmentation, such as the use of radiosensitizers, hyperthermia in conjunction with irradiation, or an interstitial supplement may be required to increase the rate of local sterilization.
在过去25年里,外照射已广泛应用于原发性前列腺癌的治疗。对于疾病明显局限于前列腺的患者(标称分期A和B;或T0、T1和T2,淋巴结状况未知),5年、10年和15年的精算生存率分别达到79%、58%和37%。对于有包膜外侵犯的患者(分期C,或T3,淋巴结状况未知),上述时间段的生存率分别为60%、36%和22%。在选择更严格的亚组患者中,例如那些直径1厘米或更小的结节性病变患者,到第8年生存率稳定在80%,目前存活时间最长的患者已超过15年。在113例结节性病变占据一个叶最多一半的患者中,15年时的生存概率略低于60%。在一组51例分期的斯坦福患者中,对首次出现转移的时间的研究与泌尿肿瘤研究组报告的手术组相当,而不是放疗组,这使人怀疑泌尿肿瘤研究组在短期随访中所显示的前列腺A2和B期癌手术和放疗结果的差异是否必然是一个基本观察结果。临床分期和组织病理学分级都与淋巴结病相关,而淋巴结病反过来又对生存有深远的不利影响。其他对生存有不利影响的因素包括治疗延迟超过6个月、放射剂量小于6500拉德和/或输尿管梗阻的证据。用外照射使原发肿瘤失活的能力似乎与疾病的体积有关,这表明,对于较大的肿瘤,仅靠外照射疗法可达到的剂量可能不足,可能需要某种形式的增强,如使用放射增敏剂、与照射联合使用热疗或间质补充,以提高局部失活率。